Showing 3911-3920 of 9301 results for "".
- Lutronic Rolls Out Derma V Dermatology Platformhttps://practicaldermatology.com/news/lutronic-rolls-out-derma-v-dermatology-platform/2460972/Lutronic is launching Derma V, a dermatology workstation that comprises a 532nm green laser, a 1064nm laser plus ICD cooling and IntelliTrack. "We created a device that brings the essential lasers that skin specialists need for their daily work - vascular, pigment and rejuvenation - into a single,…
- IFPA Calls for Action Against Psoriasishttps://practicaldermatology.com/news/ifpa-calls-for-action-against-psoriasis/2460971/Today is World Psoriasis Day, and the International Federation of Psoriasis Associations (IFPA) is launching a global petition to demand progress. In 2014, all UN nations unanimously voted to approve the Resolution on Psoriasis (WHA 67.9), committing to improve the lives of everyone living with ps…
- Potential Melanoma Treatment Breakthrough: Is KDM5B the Key?https://practicaldermatology.com/news/potential-melanoma-treatment-breakthrough-is-kdm5b-the-key/2460964/The enzyme KDM5B may suppress anti-melanoma immunity, and these findings could help lead to the development of a new treatment strategy to benefit patients with melanoma and other cancers, according to a new study out of the Yale Cancer Center in New Haven, Conn. The research is published online …
- Link Between Melanoma and Estrogen May Lead to New Therapeutic Approachhttps://practicaldermatology.com/news/link-between-melanoma-and-estrogen-may-lead-to-new-therapeutic-approach/2460953/The link between estrogens and breast cancer has long been defined, but a Duke-led research team has identified how these hormones can also influence the growth of other cancers, notably melanoma. Building on observations that male melanoma patients wh…
- Reistone’s Topical JAK Inhibitor Performs Well in Mild to Moderate ADhttps://practicaldermatology.com/news/reistones-topical-jak-inhibitor-performs-well-in-mild-to-moderate-ad/2460951/Reistone Biopharma’s SHR0302 ointment performed well in a Phase 2 study of patients with mild-to-moderate atopic dermatitis (AD), the company reports. SHR0302 ointment, a topical, selective JAK1 inhibitor, met key primary and secondary endpoints, demonstrating significant improvement in percent ch…
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using Timber's patented IPEG delivery system, in …
- Experts Highlight Need to Focus on Psoriasis Patients’ Wellbeing in Practicehttps://practicaldermatology.com/news/experts-highlight-need-to-focus-on-psoriasis-patients-wellbeing-in-practice/2460945/In addition to managing the clinical manifestations of psoriasis, clinical practices should implement an overall and holistic assessment of the wellbeing of each patient, says a panel of scientists speaking at a symposium during the European Association of Dermatology and Venereology (EADV) 30th Co…
- It's Eczema Awareness Monthhttps://practicaldermatology.com/news/its-eczema-awareness-month/2460932/Recognizing that the daily impact and overall burden of eczema for each individual can differ greatly from person to person and within a person's lifetime, the National Eczema Association (NEA) is highlighting various aspects of the disease during Eczema Awareness Month in October. NEA has launche…
- Garnier Launches New Green Beauty Campaignhttps://practicaldermatology.com/news/garnier-launches-new-green-beauty-campaign/2460931/Garnier is launching a new educational campaign on how to live a greener life with content produced by National Geographic CreativeWorks. The series, which will premiere at Expo 2020 Dubai and roll out worldwide, aims to share expert knowledge and real-world advice on key sustainability topics, re…
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disorder…